NO2627673T3 - - Google Patents
Info
- Publication number
- NO2627673T3 NO2627673T3 NO11769881A NO11769881A NO2627673T3 NO 2627673 T3 NO2627673 T3 NO 2627673T3 NO 11769881 A NO11769881 A NO 11769881A NO 11769881 A NO11769881 A NO 11769881A NO 2627673 T3 NO2627673 T3 NO 2627673T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/087—Measuring breath flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5437—IL-13
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39367710P | 2010-10-15 | 2010-10-15 | |
| US201161508723P | 2011-07-18 | 2011-07-18 | |
| PCT/EP2011/067947 WO2012049278A1 (fr) | 2010-10-15 | 2011-10-14 | Thérapies conçues pour améliorer la fonction pulmonaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2627673T3 true NO2627673T3 (fr) | 2017-12-23 |
Family
ID=44800047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO11769881A NO2627673T3 (fr) | 2010-10-15 | 2011-10-14 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130281876A1 (fr) |
| EP (1) | EP2627673B1 (fr) |
| JP (1) | JP2013544235A (fr) |
| CN (1) | CN103328506A (fr) |
| AU (1) | AU2011315499A1 (fr) |
| BR (1) | BR112013009055A2 (fr) |
| CA (1) | CA2814431A1 (fr) |
| DK (1) | DK2627673T3 (fr) |
| ES (1) | ES2645368T3 (fr) |
| HU (1) | HUE034005T2 (fr) |
| MX (1) | MX2013004212A (fr) |
| NO (1) | NO2627673T3 (fr) |
| PL (1) | PL2627673T3 (fr) |
| RU (1) | RU2013122123A (fr) |
| WO (1) | WO2012049278A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2888281T3 (pl) * | 2012-08-21 | 2019-03-29 | Sanofi Biotechnology | Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R |
| WO2015057668A1 (fr) * | 2013-10-15 | 2015-04-23 | Medimmune, Llc | Procédés de traitement de broncho-pneumopathie chronique obstructive à l'aide du benralizumab |
| WO2015112970A1 (fr) * | 2014-01-27 | 2015-07-30 | Medimmune, Llc | Dipeptidyl peptidase-4 (dpp4/cd26) comme biomarqueur périphérique de l'activation de l'il-13 dans des poumons asthmatiques |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| US10066267B2 (en) | 2014-04-11 | 2018-09-04 | Novartis Ag | Methods of selectively treating asthma using IL-13 antagonists |
| KR20170098941A (ko) | 2015-01-09 | 2017-08-30 | 메디뮨 엘엘씨 | 인간 dpp-4를 검출하기 위한 검정법 |
| CN104605857A (zh) * | 2015-02-12 | 2015-05-13 | 上海朔茂网络科技有限公司 | 一种肺功能测量方法 |
| US11390669B2 (en) | 2016-04-27 | 2022-07-19 | Abbvie, Inc. | Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies |
| AU2018227036B2 (en) * | 2017-03-01 | 2021-07-08 | Medimmune Limited | Formulations of monoclonal antibodies |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| CA3129963A1 (fr) | 2019-03-06 | 2020-09-10 | Regeneron Pharmaceuticals, Inc. | Inhibiteurs de la voie il-4/il-13 pour une efficacite amelioree dans le traitement du cancer |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| MX2022000649A (es) | 2019-07-16 | 2022-06-08 | Sanofi Biotechnology | Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r. |
| EP4189400A2 (fr) * | 2020-07-31 | 2023-06-07 | Genentech, Inc. | Méthodes de traitement d'exacerbations de maladies respiratoires inflammatoires |
| CN112341543B (zh) * | 2021-01-11 | 2021-04-23 | 广东赛尔生物科技有限公司 | 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用 |
| EP4457245A1 (fr) | 2021-12-30 | 2024-11-06 | Regeneron Pharmaceuticals, Inc. | Méthodes pour atténuer la marche atopique par administration d'un antagoniste d'il-4/il-13 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2140660A1 (fr) * | 1993-06-13 | 1994-12-22 | Uwe R. Juergens | Utilisation de composes terpeniques pour la liberation ralentie d'acide arachidonique et de mediateurs d'inflammation |
| GB0004016D0 (en) | 2000-02-22 | 2000-04-12 | Royal Brompton Hospital | Biological material and uses thereof |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| ATE492563T1 (de) * | 2004-11-17 | 2011-01-15 | Amgen Inc | Vollständige humane monoklonale antikörper gegen il-13 |
| GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
-
2011
- 2011-10-14 RU RU2013122123/10A patent/RU2013122123A/ru not_active Application Discontinuation
- 2011-10-14 JP JP2013533226A patent/JP2013544235A/ja active Pending
- 2011-10-14 AU AU2011315499A patent/AU2011315499A1/en not_active Abandoned
- 2011-10-14 HU HUE11769881A patent/HUE034005T2/en unknown
- 2011-10-14 MX MX2013004212A patent/MX2013004212A/es unknown
- 2011-10-14 DK DK11769881.1T patent/DK2627673T3/da active
- 2011-10-14 CA CA2814431A patent/CA2814431A1/fr not_active Abandoned
- 2011-10-14 ES ES11769881.1T patent/ES2645368T3/es active Active
- 2011-10-14 WO PCT/EP2011/067947 patent/WO2012049278A1/fr not_active Ceased
- 2011-10-14 PL PL11769881T patent/PL2627673T3/pl unknown
- 2011-10-14 US US13/879,261 patent/US20130281876A1/en not_active Abandoned
- 2011-10-14 NO NO11769881A patent/NO2627673T3/no unknown
- 2011-10-14 EP EP11769881.1A patent/EP2627673B1/fr not_active Not-in-force
- 2011-10-14 BR BR112013009055A patent/BR112013009055A2/pt not_active IP Right Cessation
- 2011-10-14 CN CN2011800498365A patent/CN103328506A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20130281876A1 (en) | 2013-10-24 |
| CN103328506A (zh) | 2013-09-25 |
| EP2627673B1 (fr) | 2017-07-26 |
| BR112013009055A2 (pt) | 2016-07-19 |
| MX2013004212A (es) | 2013-09-02 |
| CA2814431A1 (fr) | 2012-04-19 |
| AU2011315499A1 (en) | 2013-05-02 |
| PL2627673T3 (pl) | 2018-01-31 |
| RU2013122123A (ru) | 2014-11-20 |
| HUE034005T2 (en) | 2018-01-29 |
| EP2627673A1 (fr) | 2013-08-21 |
| WO2012049278A1 (fr) | 2012-04-19 |
| ES2645368T3 (es) | 2017-12-05 |
| JP2013544235A (ja) | 2013-12-12 |
| DK2627673T3 (da) | 2017-11-06 |